Skip to main content

Year: 2023

Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023

-Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th– -Third quarter financial information of Notable Labs, Inc. and pro forma combined financial information of Notable Labs, Ltd. will be subsequently provided via Form 8-K later in November- FOSTER CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that it has filed its Quarterly Report on Form 10-Q containing financial results for the third quarter and nine months ended September 30, 2023. Due to the timing of the closing of Notable’s merger with VBL Therapeutics in October 2023, the Form 10-Q contains financial results of pre-merger VBL Therapeutics. In October, Notable closed...

Continue reading

Stryve Foods, Inc. Reports Third Quarter Fiscal 2023 Results

Improved Adj. EBITDA Loss by 35.0% Year-over-YearRetail Dollar Sales Growth of 21.0% Year-over-Year in Measured Channels146.8% Year-over-Year Reduction in YTD Operating Expenses Shows Transformation Progress PLANO, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) — Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snack and eating platform disrupting traditional consumer packaged goods (CPG) categories, and a leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three months and nine months ended September 30, 2023. The Company’s products in the aggregate continue to outperform the category in measured channels. The most recent 24-week SPINS data reflects meaningful year-over-year improvement in measured channels with retail dollar sales increasing...

Continue reading

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update. “Gaining alignment with the FDA on our clinical development plan for oxylanthanum carbonate (OLC) was a major achievement as we are one step closer to potentially bringing a much-needed therapy to individuals living with chronic kidney disease on dialysis,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With...

Continue reading

Fluent Announces Third Quarter 2023 Financial Results

Revenue of $66.2 million for Q3 2023 and $225.6 million for YTD 2023 Gross profit (exclusive of depreciation and amortization) of $16.1 million for Q3 2023 and $57.7 million for YTD 2023 Net loss of $33.6 million for Q3 2023 and $61.3 million for YTD 2023 Media margin of $19.3 million for Q3 2023 and $67.2 million for YTD 2023 Adjusted EBITDA of negative $1.7 million for Q3 2023 and positive $4.3 million for YTD 2023 Adjusted net loss of $4.1 million for Q3 2023 and $6.8 million for YTD 2023NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the third quarter ended September 30, 2023. Don Patrick, Fluent’s Chief Executive Officer, commented, “Our third quarter results clearly reflect our post-FTC settlement transition...

Continue reading

NXT Energy Solutions Announces Third Quarter 2023 Results

CALGARY, Alberta, Nov. 14, 2023 (GLOBE NEWSWIRE) — NXT Energy Solutions Inc. (“NXT” or the “Company”) (TSX: SFD; OTCQB: NSFDF) today announced the Company’s financial and operating results for the three and nine months ended September 30, 2023. All dollar amounts herein are in Canadian Dollars unless otherwise identified. Financial and Operating Highlights Key financial and operational highlights are summarized below:on September 5, 2023. NXT announced that it has executed a contract to provide an SFD® survey to an independent oil and gas exploration company in Turkiye; the second tranche of the convertible debenture with strategic partner Ataraxia Capital contributed $0.27 million of cash; cash at September 30, 2023 was $0.37 million; net working capital was ($3.47) million at September 30, 2023; the...

Continue reading

Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023 Fortress is advancing several late-stage clinical assets with three potential NDA and BLA submissions to FDA through year-end of 2024 across our portfolio1, including a NDA submission for DFD-29 to treat rosacea, anticipated around year-end of 2023 MIAMI, Nov. 14, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2023. Lindsay A. Rosenwald, M.D., Fortress’...

Continue reading

IZEA Reports Q3 2023 Revenue of $7.9 million

ORLANDO, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), a premier provider of influencer marketing technology, data, and services for the world’s leading brands, reported its financial and operational results for the third quarter ended September 30, 2023. Q3 2023 Financial Summary Compared to Q3 2022Total revenue decreased 27.1% to $7.9 million, compared to $10.8 million Total costs and expenses decreased 13.3% to $10.5 million, compared to $12.2 million Net loss was $2.0 million, compared to a net loss of $0.9 million Adjusted EBITDA* for the quarter was $(1.5) million, compared to $(0.6) million Cash, cash equivalents and investments on September 30, 2023 totaled $62.7 million with no long-term debtQ3 2023 Operational HighlightsIZEA named “Best Influencer Marketing Company” in 2023...

Continue reading

Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023. “We shipped five G4 systems in the third quarter, our highest quarterly total yet, launched Max Read flow cell kits for single cell sequencing, and saw our largest number of quarterly consumable kit orders,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. “In the near term, we will be building our installed base more aggressively and prioritizing fewer yet higher impact products on our product roadmap. We have also cut costs to extend runway, providing time...

Continue reading

WillScot Mobile Mini to Participate in Bank of America Leveraged Finance Conference

PHOENIX, Nov. 14, 2023 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), the North American leader in innovative temporary space solutions, today announced that Tim Boswell, President and Chief Financial Officer and Matt Jacobsen, Senior Vice President of Finance, will host private investor meetings at the Bank of America Leveraged Finance Conference in Boca Raton, FL, on November 28, 2023. About WillScot Mobile Mini WillScot Mobile Mini trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative and flexible temporary space solutions. The Company’s diverse product offering includes modular office complexes, mobile offices, classrooms, temporary restrooms,...

Continue reading

Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

– RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia – – Consistent Phase 3 RECOVER and Phase 2 REFRESH findings reinforce meaningful improvements across domains, well-tolerated safety, and low discontinuation rates for brilaroxazine vs. placebo – – Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – CUPERTINO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.